| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.28 | 6e-08 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | 0.18 | 2e-06 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | -0.17 | 2e-06 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.16 | 4e-06 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.23 | 4e-06 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | 0.16 | 5e-06 |
| mRNA | SB52334 | GDSC1000 | pan-cancer | AAC | -0.17 | 6e-06 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | 0.15 | 8e-06 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.16 | 1e-05 |
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | -0.15 | 2e-05 |